Crossmark

Cost-utility analysis of a consensus and evidence-based medication review to optimize and potentially reduce psychotropic drug prescription in institutionalized dementia patients

Crossref DOI link: https://doi.org/10.1186/s12877-021-02287-7

Published: 2021-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Massot Mesquida, Mireia http://orcid.org/0000-0003-3649-5167
Folkvord, Frans http://orcid.org/0000-0001-7602-3792
Seda, Gemma http://orcid.org/0000-0002-9929-4496
Lupiáñez-Villanueva, Francisco http://orcid.org/0000-0001-5361-7678
Torán Monserrat, Pere http://orcid.org/0000-0002-9865-7427
License Information

Text and Data Mining valid from 2021-05-22

Version of Record valid from 2021-05-22
More Information

Article History

Received: 19 January 2021

Accepted: 11 May 2021

First Online: 22 May 2021

Declarations

:

: The study was approved by the Ethics and Clinical Research Committee of the Jordi Gol Primary Care Research Institute (IDIAP, <i>Institut d’Investigació en Atenció Primària Jordi Gol</i>) of the Catalan Health Institute (ICS, <i>Institut Català de la Salut,</i> Code: P15/120). This paper shows the modeling and economic evaluation of the data from the previous clinical study [CitationRef removed] and has been carried out following the guidelines and recommendations of good practice in research (ExternalRef removed). The Jordi Gol IDIAP constitutes the ethics committee for all primary care activity within the ICS. .

: Not applicable.

: All authors declare that they have no conflicts of interest related to this study.

Document is current

Any future updates will be listed below